reglab/statecodes huggingface dataset:
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 17 - STERILE COMPOUNDING › Section 17-13 - Immediate Use CSPs

Current through July 13, 2024
(a) Compounding of CSPs by pharmacy staff
				outside of a classified area or SCA for direct and immediate administration to
				patients is not subject to the requirements of this Chapter, when all of the
				following conditions are met:
(i) Aseptic
				processes are followed and written procedures are in place to minimize the
				potential for contact with nonsterile surfaces, introduction of particulate
				matter or biological fluids, and mix-ups with other conventionally manufactured
				products or CSPs;
(ii) Compounding
				is performed in accordance with the evidence-based information for physical and
				chemical compatibility of the drugs;
(iii) The preparation involves not more than
				three (3) different sterile products;
(iv) Any unused starting component from a
				single-dose container shall be discarded after preparation for the individual
				patient is complete. Single-dose containers shall not be used for more than one
				(1) patient;
(v) Administration of
				the CSP begins within four (4) hours following the start of preparation. If
				administration has not begun within four (4) hours following the start of
				preparations, it shall be promptly, appropriately, and safely discarded;
				and
(vi) Unless the CSP is
				administered by the person who prepared the CSP or administration is witnessed
				by the preparer, the CSP shall be labeled with the names and amounts of all
				active ingredients, the name or initials of the person who prepared the CSP,
				and the exact four (4) hour time period within the administration shall
				begin.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 17 - STERILE COMPOUNDING › Section 17-14 - Sterilization and Depyrogenation

Current through July 13, 2024
(a) Pharmacy staff shall sterilize all CSPs
				that contain nonsterile components or that come into contact with nonsterile
				devices during any phase of compounding, within six (6) hours after completing
				the CSP.
(b) Pharmacy staff shall
				sterilize the CSP in a method without degrading its physical and chemical
				stability or the packaging integrity.
(c) Pharmacy staff shall document a
				description of the sterilization process, including temperature, pressure (if
				applicable), duration, permissible load conditions for each cycle, the use of
				biological indicators and endotoxin challenge vials, and be readily
				retrievable.
(d) Pharmacy staff
				shall document results of terminal sterilization. Documentation shall include,
				but is not limited to, the temperature, pressure, duration, permissible load
				conditions for each cycle, and the used of biological indicators and endotoxin
				challenge vials.
(e) Equipment used
				to terminally sterilize CSPs shall be appropriately maintained, calibrated, and
				cleaned. Maintenance, calibration and cleaning shall be documented by pharmacy
				staff.
(f) Depyrogenation processes
				shall meet the following requirements:
(i)
				Depyrogenation shall be used to render glassware, metal, and other thermostable
				containers and components pyrogen-free;
(ii) The duration of the exposure period
				shall include sufficient time for the items to reach the depyrogenation
				temperature;
(iii) The items shall
				remain at the depyrogenation temperature for the durations of the
				depyrogenation period;
(iv) The
				effectiveness of the depyrogenation cycle shall be verified and documented
				initially and annually thereafter using endotoxin challenge vials to
				demonstrate the cycle is capable of achieving a 3-log reduction or more in
				endotoxins;
(v) The effectiveness
				of the depyrogenation cycle shall be re-established for any changes to the
				depyrogenation cycle; and
(vi)
				Items that are not thermostable shall be depyrogenated by rinsing with sterile,
				non-pyrogenic water, and thoroughly drained or dried immediately before use in
				compounding.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 17 - STERILE COMPOUNDING › Section 17-15 - Release Inspections and Testing

Current through July 13, 2024
(a) Pharmacy staff shall visually inspect all
				CSPs at the completion of compounding, before release and dispensing to:
(i) Determine whether the physical appearance
				of the CSP is as expected;
(ii)
				Confirm the CSP and its labeling match the prescription or medication order;
				and
(iii) Ensure the integrity of
				the container-closure system.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 17 - STERILE COMPOUNDING › Section 17-16 - Hazardous Drugs as CSPs

Current through July 13, 2024
(a) Hazardous drugs shall be prepared for
				administration only under conditions that protect personnel in the preparation
				and storage areas.
(b) Pharmacy
				staff shall store hazardous drugs separately from other inventory, in a manner
				to prevent contamination and personnel exposure.
(c) Pharmacy staff shall handle hazardous
				drugs with caution at all times using appropriate chemotherapy gloves during
				receiving, distributions, stocking, inventorying, preparation for
				administration, and disposal.
(d)
				Hazardous drugs shall be prepared in a BSC or CACI with ISO Class 5 or better
				air quality.
(e) CSTDs shall be
				used when the compounding process allows.
(f) A hazardous drug buffer room shall
				maintain a minimum differential negative pressure of 0.01-inch water column
				between the buffer room and the ante-room.
(g) The pharmacy shall limit access to areas
				where hazardous drugs are stored and prepared to protect persons not involved
				in drug preparation.
(h)
				Compounding pharmacy staff shall wear PPE when compounding in a BSC or CACI and
				when using CSTDs.
(i) PPE shall include gowns,
				face masks, eye protections, hair covers, shoe covers or dedicated shows, and
				double gloving with sterile chemo-type gloves.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 17 - STERILE COMPOUNDING › Section 17-17 - Radiopharmaceuticals as CSPs

Current through July 13, 2024
(a) Radiopharmaceuticals compounded from
				sterile components in closed, sterile containers, and with a volume of 100 mL
				or less for a single-dose injection, or no more than 30 mL taken from a
				multiple-dose container, are considered low-risk level CSPs and shall comply
				with the requirements in this Chapter.
(b) Radiopharmaceuticals shall be compounded
				using appropriately shielded vials and syringes, in a properly functioning and
				certified PEC, located in an ISO Class 8 or cleaner SEC.
(c) Radiopharmaceuticals vials designed for
				multi-use, compounded with technetium-99m, exposed to ISO Class 5 environments
				and punctured by needles with no direct contact contamination, may be used up
				to the time indicated by the manufacturer's recommendations.
(d) Technetium-99m/molybdenum-99 generator
				systems shall be stored and operated under conditions recommended by
				manufacturers, and applicable state and federal regulations.
(i) Generator systems shall be eluted in an
				ISO Class 8 or cleaner air environment, to permit special handling, shielding,
				and air flow requirements.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 18 - PRESCRIBING BY PHARMACISTS › Section 18-4 - Opiate Antagonists

Current through July 13, 2024
(a) Pharmacists may prescribe and dispense
				opiate antagonists in accordance with Board rules and W.S. §
									35-4-901 et seq.
(b) Prior to prescribing an opiate
				antagonist, a pharmacist shall successfully complete a minimum of one hour of
				an ACPE accredited continuing education program related to the use of opiate
				antagonists.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 18 - PRESCRIBING BY PHARMACISTS › Section 18-5 - Epinephrine Auto-Injectors

Current through July 13, 2024
Pharmacists may prescribe and dispense epinephrine
				  auto-injectors in accordance with Board rules and W.S. §
									35-4-901 et seq.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-3 - Scope

Current through July 13, 2024
This chapter applies to any person, partnership, corporation,
				  limited liability company, or other entity seeking licensure as a pharmacist of
				  as a pharmacy providing pharmacy services within this state.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-4 - Definitions

Current through July 13, 2024
(a) "Foreign pharmacy graduate" means a
				pharmacist whose undergraduate pharmacy degree was conferred by a recognized
				school of pharmacy outside of the United States, the District of Columbia and
				Puerto Rico. United States citizens who have completed their pharmacy education
				outside the United States are foreign pharmacy graduates. Foreign nationals who
				have graduated from schools in the United States are not foreign pharmacy
				graduates.
(b) "Institutional
				facility" means a hospital, convalescent home, nursing home, extended care
				facility, correctional or penal facility, or any other organization, public or
				private, which provides a physical environment for patients to obtain medical,
				surgical, and/or nursing services, except those places where physician,
				dentists, veterinarians, or other practitioners of the healing arts engage in
				private office practice.
(c)
				"Institutional Pharmacy" means a pharmacy where medications are dispensed to
				other health care professionals for administration to institutionalized
				patients served by an institutional facility, and which is:
(i) Located within the institutional
				facility, or
(ii) Located outside
				the institutional facility but only provides pharmacy services to
				institutionalized patients.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-5 - Pharmacist Licensure by Examination

Current through July 13, 2024
(a) The Board shall utilize those
				standardized examinations as prepared and administered by the National
				Association of Boards of Pharmacy (NABP). These standardized examinations shall
				include the following:
(i) North American
				Pharmacist Licensing Examination (NAPLEX®); and
(ii) Multistate Pharmacy Jurisprudence
				Examination (MPJE®).
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-6 - Pharmacist Licensure by Reciprocal License Transfer

Current through July 13, 2024
(a) Any pharmacist, who is licensed by
				examination and is in good standing in any state which is a member of the NABP
				and who desires to be licensed by reciprocity into this state, shall proceed in
				the manner outlined by the NABP after first submitting the "Preliminary
				Application for Transfer of Pharmacist Licensure" obtained from the NABP.
(i) All candidates for license transfer shall
				be required to:
(A) File all appropriate
				applications with the Board;
(B)
				Pay the required application fee;
(C) Complete the two (2) fingerprint cards
				provided by the Board for the criminal background check;
(D) Pay the required criminal background
				check fee;
(E) Pass the MPJE®
				for Wyoming;
(F) Prove good moral
				character;
(G) Prove they have been
				in active pharmacy practice, as defined in this chapter, for the year preceding
				the date of their application for license transfer. Applicants failing to show
				proof must complete an internship in Wyoming approved by the Board of no less
				than four hundred (400) hours;
(H)
				Meet all requirements under the Wyoming Pharmacy Act and these rules;
				and
(I) If applying as a foreign
				pharmacy graduate, possess a FPGEC® Certificate.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-7 - Reinstatement of Registered Pharmacist License After Failure to Renew, Returning from Inactive Status, Issuance of Duplicate License

Current through July 13, 2024
(a) If a person requests reinstatement of
				their registered pharmacist license when said license has lapsed only for
				failure to pay renewal fees, the person shall:
(i) Write a letter requesting consideration
				of reinstatement;
(ii) Pay all back
				renewal fees, including annual fines, up to a maximum of five (5)
				years;
(iii) Provide copies of
				approved continuing education (CE) certificates for those years the license was
				lapsed, to a maximum of five (5) years. All CE certificates must be from
				approved providers;
(iv) Provide at
				least two (2) recent letters from a pharmacist or a pharmacy owner attesting to
				good character;
(v) If licensed
				outside Wyoming, provide a letter from the board of pharmacy in the state where
				licensed and currently practicing. This letter must state current license
				status and indicate if the license has been subject to any investigation or
				disciplinary action by the Board;
(vi) Complete two (2) fingerprint cards,
				provided by the Board, and include a check made payable to the Wyoming State
				Board of Pharmacy in the amount of fifty dollars ($50.00) to cover the cost of
				the criminal background history; and
(vii) Provide a notarized employer affidavit
				attesting to the active practice of pharmacy in the year preceding the date of
				the application for reinstatement. Active practice requires that the pharmacist
				work a minimum of four hundred (400) hours during this time period.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-8 - Reinstatement of a Revoked or Suspended Pharmacist or Pharmacy Technician License

Current through July 13, 2024
(a) A pharmacist or pharmacy technician whose
				license has been revoked or suspended by the Board may file an application, on
				a form supplied by the Board, requesting a hearing to present evidence to show
				why the license should be reinstated subject to the following:
(i) A pharmacist or pharmacy technician whose
				license was revoked by the Board may not file an application requesting a
				hearing until thirty-six (36) months have elapsed from the date the order
				revoking the pharmacist or pharmacy technician license became final;
(ii) A pharmacist or pharmacy technician
				whose license was suspended by the Board may not file an application requesting
				a hearing until one-half (1/2) of the suspension so ordered by the Board has
				elapsed;
(iii) A pharmacist shall
				submit an application fee of two hundred fifty dollars ($250.00) and pay for
				the cost of the hearing, if the Board issues an order denying reinstatement.
				The application fee is nonrefundable;
(iv) A pharmacy technician shall submit an
				application fee of one hundred twenty five dollars ($125.00) and pay for the
				cost of the hearing, if the Board issues an order denying reinstatement. The
				application fee is nonrefundable;
(v) The applicant must complete all questions
				and provide all information requested on the application;
(vi) An incomplete application and the
				accompanying fee will be returned and a hearing date will not be set by the
				Board; and
(vii) In the
				application, the pharmacist or pharmacy technician shall authorize any health
				professional who has examined or treated the applicant to disclose a diagnosis
				and the reasons for it to the Board and the Board staff.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-9 - Licensing of Facilities

Current through July 13, 2024
(a) Prior to the issuing of the registration
				to operate a pharmacy or prescription department in Wyoming, the Board will
				inspect the pharmacy for minimum standards including space, fixtures,
				sanitation, reference library, technical equipment and security. The
				application will include the number of hours the pharmacy will be in operation
				per week.
(b) The facility
				application shall list the names of all licensed pharmacists employed,
				specifically identifying the Pharmacist-in-Charge (PIC). The PIC determines
				which employees shall have access to the pharmacy.
(c) The Board shall be notified within seven
				(7) days of every change in PIC. A controlled substance inventory is required
				when there is a change in PIC, at the time of the change. This inventory shall
				include the signatures of both the outgoing and incoming PIC, and the date and
				time the inventory was taken. If the inventory cannot be conducted with both
				pharmacists, then the incoming PIC shall conduct an inventory. A copy of the
				controlled substance inventory and signed Certification of Responsibilities as
				Pharmacist-in-Charge (PIC) shall be forwarded to the Board office within
				fifteen (15) days of conducting the inventory.
(d) When a pharmacy changes ownership, the
				original license becomes void and a new license must be secured by the new
				owner or owners. A new license is required even if there is no change in the
				name of the pharmacy or in the registered PIC of the pharmacy.
(e) In the case of a corporation, limited
				liability company or partnership holding a pharmacy license, the Board shall be
				notified and a new license applied for any time the majority of stock in the
				corporation is sold or a majority of the partners of the partnership or members
				of the limited liability company change. This shall constitute new ownership.
				Requirements for the change of ownership are the same as outlined in this
				section.
(f) A pharmacy license
				registers the pharmacy to which it is issued only at the location specified on
				the application and is not transferable.
(g) The Board shall be notified in writing at
				least thirty (30) days before a pharmacy change of address. The new location
				shall be inspected by the Board prior to issuance of an amended pharmacy
				license for the new location. The new location must meet all requirements for a
				new or remodeled pharmacy, as noted in this chapter.
(h) All licenses and certificates issued by
				the Board shall be displayed in a prominent place in the facility and always in
				view of the public.
(i) Resident
				Pharmacy Licenses shall indicate "Institutional" or "Retail."
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-11 - Specific Requirements for Licensure of Non-Resident Pharmacies to Ship Prescription Drugs into the State

Current through July 13, 2024
(a) Any pharmacy operating from outside this
				State that ships, mails or delivers, in any manner, a dispensed prescription
				drug or legend drug to a patient in this State shall obtain and hold a
				non-resident pharmacy license and, if applicable, a controlled substance
				registration.
(b) Said pharmacy
				license and controlled substance application shall be on forms supplied by the
				Board staff and shall be accompanied by the following information:
(i) A copy of the pharmacy license from the
				state of residence;
(ii) A copy of
				the latest inspection report from the state of residence;
(iii) A copy of current DEA
				registration;
(iv) A list of
				partners, members, or principal officers and registered agent for service of
				process, if any; and
(v) A list of
				all registered pharmacists and pharmacy technicians, specifying the
				PIC.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 19 - LICENSING OF PHARMACISTS AND PHARMACIES › Section 19-13 - Institutional Pharmacy Closure

Current through July 13, 2024
(a) Not less than twenty-one (21) days prior
				to an institutional pharmacy licensed by the Board permanently ceasing
				operation, the Board shall receive written notice of the following:
(i) The last day the institutional pharmacy
				will be open for business;
(ii) The
				proposed disposition of all prescription drug inventory including controlled
				and non-controlled prescription drug products;
(iii) The name, address and telephone number
				of the custodian of records for the following documents, which must be
				maintained for two (2) years from the date of closure:
(A) Completed DEA 222 forms or retrievable
				electronic equivalent;
(B) Invoices
				for purchases of Schedule III, IV and V controlled substances; and
(C) Patient specific records.
(iv) The date the DEA was
				contacted regarding the closure and confirmation that all invoices and DEA 222
				forms referencing the sale of controlled substances at closure, blank DEA 222
				forms and the DEA registration certificate were delivered to the regional DEA
				office.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 20 - COLLABORATIVE PRACTICE REGULATIONS › Section 20-4 - Definitions

Current through July 13, 2024
(a) "Collaborative pharmacy practice" is that
				practice of pharmacy whereby one or more pharmacists have jointly agreed, on a
				voluntary basis, to work in conjunction with one or more practitioners under
				protocol and in collaboration to provide patient care services to achieve
				optimal medication use and desired patient outcomes.
(b) "Collaborative practice agreement" means
				a written voluntary agreement, between a pharmacist and a prescribing
				practitioner that defines a collaborative practice.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 20 - COLLABORATIVE PRACTICE REGULATIONS › Section 20-5 - Collaborative Pharmacist Care

Current through July 13, 2024
(a) A pharmacist planning to engage in
				collaborative practice shall have on file at the pharmacist's place of practice
				a written, signed collaborative practice agreement approved by the Board. This
				collaborative practice agreement allows the pharmacist, acting within the
				pharmacist's collaborative scope of practice, to conduct MTM approved by a
				prescribing practitioner acting within the scope of the practitioner's current
				practice.
(b) The collaborative
				practice agreement shall include:
(i) The
				names of the prescribing practitioner and the pharmacist who are parties to the
				collaborative practice agreement;
(ii) The specific types of MTM decisions that
				the pharmacist is allowed to make, which shall include:
(A) The types of diseases, drugs or drug
				categories involved, and the extent of MTM allowed in each case;
(B) The methods, procedures, decision
				criteria and plan the pharmacist is to follow when conducting MTM;
				and
(C) The procedures the
				pharmacist is to follow in the course of conducting MTM, including
				documentation of decisions and a plan or appropriate mechanism for
				communication and reporting to the prescribing practitioner concerning specific
				decisions. Documentation of decisions shall occur in the prescribing
				practitioner patient medical record. If the medical record is not available at
				the practice site, a copy of the documentation of decisions will be sent to the
				prescribing practitioner.
(iii) A method for the prescribing
				practitioner to monitor compliance with the collaborative practice agreement
				and clinical outcomes when MTM by the pharmacist has occurred and to intercede
				when necessary;
(iv) A provision
				that allows the prescribing practitioner to override the collaborative practice
				agreement whenever deemed necessary or appropriate;
(v) A provision allowing the practitioner,
				pharmacist and patient or patient's agent, parent or guardian to cancel the
				collaborative practice agreement at any time by written notice to all parties.
				The pharmacist shall retain the original notice of cancellation for two (2)
				years; and
(vi) The signatures of
				the pharmacist and prescribing practitioner who are entering into the
				collaborative practice agreement and the dates when signed.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 21 - FEES › Section 21-2 - General Information

Current through July 13, 2024
(a) Fees shall be payable in the exact amount
				and shall be paid in advance of the licensing services rendered.
(b) All fees collected by the Board are
				non-refundable.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0001 - Pharmacy, Board of › Chapter 21 - FEES › Section 21-3 - Fees

Current through July 13, 2024
(a) The Board shall charge the following
				fees:
(i) Pharmacist licensure by examination
				or re-examination is seventy-five dollars($75.00). This is separate from fees
				paid to the NABP for the NAPLEX® and the MPJE®.
(ii) Pharmacist licensure by reciprocity is
				two hundred dollars ($200.00). This is separate from fees paid to the NABP for
				the NAPLEX® and the MPJE®.
(iii) Pharmacist licensure renewal is one
				hundred dollars ($100.00) per year;
(iv) Pharmacy intern licensure is fifteen
				dollars ($15.00) per year;
(v)
				Pharmacy technician licensure and renewals are fifty dollars ($50.00) per
				year;
(vi) Pharmacy
				technician-in-training permit is fifteen dollars ($15.00);
(vii) Resident retail pharmacy license and
				renewals are one hundred fifty dollars ($150.00) per year;
(viii) Non-resident pharmacy license and
				renewals are three hundred dollars ($300.00) per year;
(ix) A prescription drug manufacturer,
				distributor, reverse distributor, or wholesaler license and renewals are two
				hundred seventy-five dollars ($275.00) per year;
(x) Medical oxygen manufacturer or
				distributor license and renewals are one hundred dollars ($100.00) per
				year;
(xi) Outsourcing facilities
				license and renewals are three hundred dollars ($300.00) per year;
(xii) Third party logistics provider license
				and renewals are two hundred seventy-five dollars ($275.00) per year;
(xiii) Wholesale distributors of prescription
				drugs for non-human use license and renewals are two hundred seventy-five
				dollars ($275.00) per year;
(xiv)
				Methamphetamine precursor retail distributor license and renewals are
				twenty-five dollars ($25.00) per year;
(xv) Ancillary drug supply permit and
				renewals are twenty-five dollars ($25.00) per year;
(xvi) Institutional pharmacy license and
				renewals are one hundred fifty dollars ($150.00) per year;
(xvii) The Board shall charge a two hundred
				fifty-dollar ($250.00) fee for preparing and sending mailing lists of
				pharmacists, pharmacy technicians, pharmacy interns, pharmacy
				technicians-in-training, pharmacies, controlled substance registrants and drug
				distributors. Each list shall constitute a separate mailing list. Federal and
				state agencies shall be exempt from payment of fees for mailing
				lists;
(xviii) The Board shall
				charge a thirty-five-dollar ($35.00) fee to verify the license of any
				non-resident pharmacy, manufacturer, distributor, wholesaler or reverse
				distributor; and
(xix) Duplicate
				licenses may be issued upon a licensee's request. There shall be a
				twenty-five-dollar ($25.00) fee charged for the duplicate license.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 1 - AUTHORITY AND DEFINITIONS › Section 1-1 - Authority

Current through July 13, 2024
These rules and regulations are adopted as authorized by the
				  Wyoming Administrative Procedure Act,
				  W.S.
				  16-3-101 through
				  16-3-115; and the Wyoming
				  Controlled Substances Act, W.S. W.S.
				  W.S.
				  35-7-1001 through
				  35-7-1055.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 1 - AUTHORITY AND DEFINITIONS › Section 1-2 - Definitions

Current through July 13, 2024
As used herein, the following terms shall have the meanings
				  specified:
(a) The term "Act" means the
				Wyoming Controlled Substances Act.
(b) The term "Bureau" means the Drug
				Enforcement Administration, United States Department of Justice.
(c) The term "person" includes any
				individual, corporation, government or governmental subdivision or agency
				business trust, partnership, association or other legal entity.
(d) The term "pharmacist" means any
				pharmacist licensed by the Board to dispense controlled substances, and shall
				include any other person (e.g., a pharmacist intern) authorized by the Board to
				dispense controlled substances under the immediate supervision of a pharmacist
				licensed by the Board.
(e) The term
				"prescription" means an order for medication which is dispensed to or for an
				ultimate user but does not include an order for medication which is dispensed
				for immediate administration to the ultimate user. (E.g., an order to dispense
				a drug to a bed patient for immediate administration in a hospital is not a
				prescription.)
(f) The term
				"registrant" means any person who is registered pursuant to either Sections 24
				and 25 of the Act or Section 302 of the Federal Act.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 1 - AUTHORITY AND DEFINITIONS › Section 1-3 - Principal Reasons for Adoption of Rules

Current through July 13, 2024
The adoption of rules requiring registration of persons
				  engaged in the manufacture, distribution or dispensing of controlled substances
				  is deemed to be in the public's interest in the regulation of such
				  activities.
To implement such regulation the rules specifically provide
				  for and establish:
(a) Requirements
				pertaining to registration of persons manufacturing, distributing and
				dispensing controlled substances, and provide for exemption from registration
				designated classes.
(b)
				Requirements relating to maintaining records of inventories and safeguarding
				inventories.
(c) Requirements
				governing the issuing, filing and filling of prescriptions containing
				controlled substances.
(d)
				Procedures for Administrative Inspection of inventories and records.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-1 - Hearings Generally

Current through July 13, 2024
In any case where the Commissioner, or his designee shall
				  hold a hearing on the issuance, amendment, or repeal of rules pursuant to the
				  Act, the procedures for such hearing and accompanying proceedings shall be
				  governed generally by the rule making procedures set forth in the Wyoming
				  Administrative Procedure Act
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-2 - Burden of Proof

Current through July 13, 2024
At any hearing held under the provisions of the Act, the
				  proponent for the issuance, amendment, or repeal of any rule or regulation
				  shall have the burden of proof.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-3 - Control Required by Statute

Current through July 13, 2024
(a) In the event
				that the Bureau has published in the Federal Register a final order
				designating, rescheduling, or deleting any substance as a controlled substance
				under the Federal Controlled Substances Act (21 U. S. C., 811), the
				Commissioner, pursuant to Section 11(d) of the Act may either:
(i) Within thirty (30) days after the
				publication of the final order in the Federal Register, object to designating,
				rescheduling, or deleting the substance in the same manner under the Act,
				or
(ii) After thirty (30) days
				following the publication of the final order in the Federal Register, issue a
				final order designating, rescheduling, or deleting the substance in the same
				manner without regard to findings required under Section 11(b) of the
				Act.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-4 - Complaints

Current through July 13, 2024
(a) A disciplinary action is initiated
				against a license holder by submitting a written complaint to the Board office.
				A complaint concerning an alleged violation of the Act or Board Rules may be
				submitted by any person or entity, a Board member, or a Board staff member. The
				written complaint should provide as much of the following information as may be
				available and applicable:
(i) The name and
				address of the complainant;
(ii)
				The name, address, place of employment, and telephone number of the license
				holder against whom the charges are made;
(iii) The specific conduct alleged to
				constitute the violation;
(iv) The
				name and address of any other witnesses; and
(v) The signature of the
				complainant.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-5 - Review of Written Complaint

Current through July 13, 2024
(a) Written
				complaints shall be referred to the Board staff Compliance Officer/Investigator
				or to an Investigative Board Member (IBM) selected by Board staff from a
				rotating schedule. License holders against whom charges are made will be
				advised of the investigation and the nature of the complaint.
(i) The IBM shall not take part in the
				consideration of any contested case.
(ii) The IBM shall not, by this rule, be
				barred from attending any disciplinary hearing.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-6 - Investigations and Board Action

Current through July 13, 2024
Board staff shall investigate those written complaints
				  received which merit further investigation.
(a) Upon completion of the investigation the
				Executive Director shall:
(i) Dismiss the
				complaint if no evidence of violation of the Act or Board rules is found;
				or
(ii) Prepare an investigative
				report which shall include:
(A) The
				findings;
(B) A list of statutes
				and/or Board rules believed to have been violated; and
(C) Any relevant additional
				information.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-7 - Service of Notice and Opportunity to Show Compliance

Current through July 13, 2024
Prior to commencement of a formal hearing, the IBM Executive
				  Director shall give notice by mail to the license holder of the facts or
				  conduct which warrant his/her intended action. The notice shall give the
				  license holder an opportunity to show compliance with all lawful requirements
				  for retention of the license within twenty (20) days of the mailing of the
				  notice. Such notice shall be sent to the license holder's last known address
				  both by certified mail with return receipt requested and by first class
				  mail.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-8 - Formal Hearing Procedures Prerequisites

Current through July 13, 2024
(a) Formal
				proceedings for a hearing before the Board regarding action against a license
				holder shall be commenced by petition and notice of hearing, served in person,
				or by both certified mail and first class mail sent to the address last known
				by the Board at least thirty (30) days prior to the date set for the hearing.
				The petition and notice shall contain at least:
(i) The name and address of the license
				holder;
(ii) A statement, in
				ordinary and concise language, of the nature of the complaint filed with the
				Board, the facts upon which the complaint is based, as well as the specific
				statute(s) or Board rules and regulations alleged to have been
				violated;
(iii) The time, place,
				and nature of the hearing;
(iv)
				That the hearing is being held pursuant to the authority provided by W.S.
				§
										
											33-24-101 through
				33-24-301.
(v) The license holder shall file an Answer
				or Notice of Appearance, which must be received by the Board at least ten (10)
				working days prior to the date set for hearing, or the license holder will be
				in default.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-9 - Default

Current through July 13, 2024
The Board may enter an order based on the allegations in a
				  petition in any case where the applicant or license holder has not answered or
				  appeared in writing ten (10) working days before the hearing, or in any case in
				  which the applicant or license holder or his/her representative has not
				  appeared at a scheduled hearing for which they had notice.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-10 - Contested Case Hearings

Current through July 13, 2024
The Office of Administrative Hearings shall act as the
				  hearing officer and shall preside over the formal contested case hearing which
				  shall be conducted pursuant to the Wyoming Administrative Procedure Act and the
				  Office of Administrative Hearings' rules concerning contested case
				  proceedings.
(a) At the Board's
				discretion, contested case hearings shall either be conducted in the presence
				of a quorum of Board Members or a committee of one (1) or more Board
				Members.
(b) During the formal
				contested case hearing, Board Members may ask questions of the witnesses and/or
				the parties including their attorneys.
(c) A court reporter shall be present during
				the hearing and report the entire proceeding.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-11 - Decisions

Current through July 13, 2024
(a) Proposed Decisions:
(i) At the discretion and direction of the
				Board hearing officer, the parties may file proposed findings of fact,
				conclusions of law, and order after the hearing and before the deadline
				announced in the hearing's closing announcements.
(ii) At the discretion and direction of the
				Board, the hearing officer or the Assistant Attorney General assigned to advise
				the Board shall prepare proposed findings of fact, conclusions of law, and
				order following deliberations by the Board or its committee.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 2 - HEARINGS › Section 2-13 - Transcripts

Current through July 13, 2024
If a Petition for Judicial Review is filed in the district
				  court, the petitioner shall either arrange the preparation and pay for the
				  transcript of the testimony, or reimburse the Board for the cost of the
				  transcript if previously prepared at Board expense.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 3 - FEES FOR REGISTRATION AND RE-REGISTRATION › Section 3-1 - Fee Amounts

Current through July 13, 2024
(a) For each
				registration or re-registration to manufacture controlled substances, the
				registrant shall pay a fee of $250.00.
(b) For each registration or re-registration
				to distribute controlled substances, the registrant shall pay a fee of
				$250.00.
(c) For each registration
				or re-registration to dispense, or to conduct research or instructional
				activities with controlled substances listed in Schedules II through V, the
				registrant shall pay a fee of $40.00 per year.
(d) For each registration or re-registration
				to conduct research or instructional activities with a controlled substance
				listed in Schedule I, the registrant shall pay a fee of $40.00 per
				year.
(e) For each registration or
				re-registration to conduct chemical analysis with controlled substances listed
				in any schedule, the registrant shall pay a fee of $40.00 per year.
(f) Any Federal, State, or local governmental
				agency may be exempted in the discretion of the Board from the payment of a
				registration fee under this section.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 3 - FEES FOR REGISTRATION AND RE-REGISTRATION › Section 3-2 - Time and Method of Payment; Delinquency Fee; Refund

Current through July 13, 2024
Registration and re-registration fees shall be paid at the
				  time when the application for registration or re-registration is submitted for
				  filing. Payment shall be made in the form of a personal, certified, or
				  cashier's check or money order, or credit card using the online renewal
				  process, made payable to the Wyoming State Board of Pharmacy. A delinquency fee
				  of $40.00 shall be assessed against any registrant that does not re-register by
				  June 30th of that renewal period. In the event that the application is not
				  accepted for filing or is denied, the payment shall be refunded to the
				  applicant. If the check is returned for any reason, the registration issued to
				  the applicant shall be deemed invalid.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 3 - FEES FOR REGISTRATION AND RE-REGISTRATION › Section 3-3 - Persons Exempt from Fee

Current through July 13, 2024
(a) The Board may
				exempt from payment of a fee for registration or re-registration the following
				persons:
(i) Any official or agency of the
				United States Army, Navy, Marine Corps, Air Force, Coast Guard, Veterans'
				Administration or Public Health Service who or which is authorized to procure
				or purchase controlled substances for official use; and
(ii) Any official, employee, or other civil
				officer or agency of the United States, of any State, or any political
				subdivision or agency thereof, who or which is authorized to purchase
				controlled substances, to obtain such substances from official stocks, to
				dispense or administer such substances, to conduct research, instructional
				activities, or chemical analysis with such substances, or any combination
				thereof, in the course of his or its official duties or employment.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 3 - FEES FOR REGISTRATION AND RE-REGISTRATION › Section 3-4 - Persons Required to Register

Current through July 13, 2024
Every person who manufactures, distributes or dispenses any
				  controlled substance or who proposes to engage in the manufacture, distribution
				  or dispensing of any controlled substance shall obtain annually a registration
				  unless exempted by law or by the regulations. Only persons actually engaged in
				  such activities are required to obtain a registration; related or affiliated
				  persons who are not engaged in such activities are not required to be
				  registered. (For example, a stockholder of a parent corporation of a
				  corporation manufacturing controlled substances is not required to obtain a
				  registration.)
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 3 - FEES FOR REGISTRATION AND RE-REGISTRATION › Section 3-5 - Separate Registration for Independent Activities

Current through July 13, 2024
(a)
				The following six groups of activities are deemed to be independent of each
				other:
(i) Manufacturing controlled
				substances;
(ii) Distributing
				controlled substances;
(iii)
				Dispensing, conducting research with (other than research described in
				subparagraph (4) of this paragraph), and conducting instructional activities
				with controlled substances listed in Schedules II through V;
(iv) Conducting research with narcotic drugs
				listed in Schedules II through V for the purpose of continuing the dependence
				on such drugs of a narcotic drug dependent person in the course of conducting
				an authorized clinical investigation in the development of a narcotic addict
				rehabilitation program pursuant to a Notice of Claimed Investigational
				Exemption for a New Drug approved by the Food and Drug
				Administration;
(v) Conducting
				research and instructional activities with controlled substances listed in
				Schedule I; and
(vi) Conducting
				chemical analysis with controlled substances listed in any schedule.
Wyoming Administrative Code › Agency 059 - Pharmacy, Board of › Sub-Agency 0002 - Commissioner of Drugs and Substances Control › Chapter 3 - FEES FOR REGISTRATION AND RE-REGISTRATION › Section 3-6 - Separate Registrations for Separate Locations

Current through July 13, 2024
(a) A
				separate registration is required for each principal place of business or
				professional practice at one general physical location where controlled
				substances are manufactured, distributed, or dispensed by a person.
(b) The following locations shall be deemed
				not to be places where controlled substances are manufactured, distributed, or
				dispensed:
(i) A warehouse where controlled
				substances are stored by or on behalf of a registered person, unless such
				substances are distributed directly from such warehouse to registered locations
				other than the registered location from which the substances were delivered or
				to persons not required to register by virtue of subsection 24(c)(ii) of the
				Act;
(ii) An office used by agents
				of a registrant where sales of controlled substances are solicited, made, or
				supervised but which neither contains such substances (other than substances
				for display purposes of lawful distribution as samples only) nor serves as a
				distribution point for filling sales orders; and
(iii) An office used by a practitioner (who
				is registered at another location) where controlled substances are prescribed
				but neither administered nor otherwise dispensed as a regular part of the
				professional practice of the practitioner at such office, and where no supplies
				of controlled substances are maintained.